Overview and Scope
Radiopharmaceuticals refer to a medication used to treat or diagnose diseases, including cancer, that contains a radioactive material. Likewise known as radioactive medication. These are the procedures used to identify certain illnesses or detect medical issues. The patient may receive them in a number of different ways. They could be injected, injected orally, or injected into the eye or bladder, for instance.
Sizing and Forecast
The radiopharmaceuticals market size has grown steadily in recent years. It will grow from $6.46 billion in 2023 to $6.77 billion in 2024 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rise in healthcare expenditure, government initiatives, convenience of treatment, and changes in lifestyles.
The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $10.59 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing geriatric population, increasing prevalence of cancer and cardiovascular diseases, high capital investments, and new product launches. Major trends in the forecast period include collaborating with other companies to boost revenues and improve product quality, investing in plant capacity expansions to cater to the increasing demand, investing in new technologies to meet the emerging demands, adopting 3d printing technology in manufacturing to save costs, invest in innovations, such as theranostics, and establish category leadership, explore in silico modeling for a more rational and scientific approach, invest in ai to reduce r&d costs and save drug development time, invest in technologies catering to cardiology to boost revenues and accept disease-specific approaches for accurate and timely diagnosis of cancer.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-global-market-report
Segmentation & Regional Insights
The radiopharmaceuticals market covered in this report is segmented –
1) By Type: Diagnostic, Therapeutic
2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications
3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes
North America was the largest region in the global radiopharmaceuticals market in 2023. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3471&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of cancer and cardiovascular diseases is projected to drive the demand for the radiopharmaceuticals market. Radiopharmaceuticals are emerging as a safe and effective therapeutic option over conventional medicines. Radiopharmaceuticals provide an upper hand to radiologists to treat cancer and cardiovascular diseases due to their benefits such as targeted therapy. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. According to the International Agency for Research on Cancer (IARC), by 2040, the global burden is projected to increase to 27.5 million active cancer incidents and 16.3 million cancer deaths primarily due to population growth and aging. About 70% of deaths from cancer occur in low- and middle-income countries. Thus, the rising cases of cancer and cardiovascular diseases are expected to surge the demand for radiopharmaceuticals for the treatment of these diseases.
Key Industry Players
Major companies operating in the radiopharmaceuticals market report are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, ÚJV Řež, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacýbaþý-Monrol Nuclear Products, NTP Radioisotopes.
The radiopharmaceuticals market report table of contents includes:
1. Executive Summary
2. Radiopharmaceuticals Market Characteristics
3. Radiopharmaceuticals Market Trends And Strategies
4. Radiopharmaceuticals Market – Macro Economic Scenario
5. Global Radiopharmaceuticals Market Size and Growth
.
.
.
32. Global Radiopharmaceuticals Market Competitive Benchmarking
33. Global Radiopharmaceuticals Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Radiopharmaceuticals Market
35. Radiopharmaceuticals Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
